NeoGenomics, Inc.

As of June 30, 2026, NeoGenomics, Inc. carries a market capitalization of 1.64B, placing it among publicly traded companies globally. Its enterprise value stands at 1.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NeoGenomics, Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, NeoGenomics, Inc. has 127.92M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.46, and the price-to-book ratio stands at 2.38.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.90B versus a market cap of 1.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NeoGenomics, Inc. maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.06, indicating elevated leverage, while an interest coverage ratio of -1.16 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. posted a negative return on equity (ROE) of -6.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.78, reflecting losses generated across the asset base. The company generates approximately 276,593.00 in revenue per employee across its workforce of 2,425.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 14.02 indicates how many times NeoGenomics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. recorded an income tax benefit of -2.34M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -47.74M and -45.41M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, NeoGenomics, Inc.'s stock has gained approximately 63.60% over the past 52 weeks. The 50-day moving average sits at 15.36, while the 200-day moving average is 11.00.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. generated 670.74M in revenue and converted that into -45.41M in net income, yielding earnings per share of -0.35. EBITDA reached -2.61M, while operating income came in at -53.16M.

As of June 30, 2026, NeoGenomics, Inc. holds 127.39M in cash and equivalents against 392.46M in total debt, resulting in a net debt position of 200.18M. Total book value stands at 687.75M, with working capital of 241.23M providing operational flexibility.

NeoGenomics, Inc. produced 19.30M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -25.74M in capital expenditures, free cash flow totaled -6.44M - equivalent to -0.05 per share.

Over the twelve months ended June 30, 2026, NeoGenomics, Inc. posted a gross margin of 43.92, reflecting its pricing power and cost economics. The operating margin of -7.92 and net profit margin of -6.77 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NeoGenomics, Inc. shareholders.

NeoGenomics, Inc.'s most recent stock split took place on April 16, 2003 with a 100:1 split ratio.

As of June 30, 2026, NeoGenomics, Inc. has an Altman Z-Score of 2.46, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.